The Art of
Licensing
About Helsinn
• Board of Directors and Top Management
• Contacts
• News
2008
2009
2010
Our locations
• Switzerland
• Ireland
• USA
Helsinn's recent history
The Art of
Development
Building pharmaceuticals
Our R&D
The Art of
Access
Making pharmaceuticals available
Our products
• Cancer Supportive Care
Palonosetron
Gelclair
Netupitant
Anamorelin
ZP1846
• Pain and Inflammation
Nimesulide
Oxaprozin
Rapid Absorption Platform
• Gastroenterology
Palonosetron
Klean-Prep
Ipamorelin
ST-1141
• Areas under development
Urology
The Ghrelin Family
The Art of
Manufacturing
High standard technologies
Helsinn Advanced Synthesis SA, Biasca
Helsinn Birex Pharmaceuticals Ltd, Dublin
The Art of
Partnership
Shaping alliances
• Our partners
Home
>
The Art of Licensing
>
About Helsinn
>
News
>
2010
2010
HELSINN ANNOUNCES THE OFFICIAL OPENING OF ITS NEW R&D CENTRE OF EXCELLENCE IN DUBLIN
01.09.2010
HELSINN ANNOUNCES THE OFFICIAL OPENING OF ITS NEW R&D CENTRE OF EXCELLENCE IN DUBLIN
09.06.2010
Helsinn Healthcare S.A. and Eisai Inc. Extend Relationship
08.07.2010
HELSINN AND MUNDIPHARMA SIGN NEW CONTRACT FOR PALONOSETRON IN ASIAN COUNTRIES
26.04.2010
HELSINN AND VIFOR PHARMA SIGN NEW CONTRACT FOR GELCLAIR IN SWITZERLAND
22.04.2010
THE 5-HT3 RECEPTOR ANTAGONIST ALOXI® LAUNCHED IN JAPAN
02.02.2010
Helsinn Chemical Operations is constantly becoming more environmentally friendly
20.01.2010
ONCOLOGY: PALONOSETRON APPROVED IN JAPAN, SECOND PHARMACEUTICAL MARKET WORLDWIDE
Copyright © Helsinn Group - Legal Statement
Last Update: 09.09.2010
About Helsinn
Our Products
Our Partners